Levodopa-induced dyskinesias in patients with Parkinson's disease: Filling the bench-to-bedside gap

The Lancet Neurology

Volumn 9, Issue 11, 2010, Pages 1106-1117

  Calabresi, Paolo ^a   Filippo, Massimiliano Di ^a   Ghiglieri, Veronica ^b   Tambasco, Nicola ^a   Picconi, Barbara ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; AMPA RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENDOCANNABINOID; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR ANTAGONIST; ISTRADEFYLLINE; LEVODOPA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PERAMPANEL; PRAMIPEXOLE; RAPAMYCIN; SARIZOTAN; SEROTONIN 1A AGONIST; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

COGNITIVE DEFECT; DISABILITY; DISEASE DURATION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; HUMAN; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE;

ANIMALS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE; RECEPTORS, DOPAMINE;

EID: 77957966489     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70218-0     Document Type: Review

References (104)

1. Cotzias GC, Papavasiliou PS, Gellene R Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 1969, 280:337-345.
2. Fahn S The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000, 47(4 suppl 1):S2-S9.
3. Mones RJ, Elizan TS, Siegel GJ Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism. J Neurol Neurosurg Psychiatry 1971, 34:668-673.
4. Linazasoro G New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 2005, 26:391-397.
5. Dodel RC, Berger K, Oertel WH Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001, 19:1013-1038.
6. Olanow CW, Obeso JA, Stocchi F Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006, 5:677-687.
7. Cenci MA L-dopa-induced dyskinesia: cellular mechanisms and approaches to treatment. Parkinsonism Relat Disord 2007, 13(suppl 3):S263-S267.
8. Jenner P Molecular mechanisms of L-dopa-induced dyskinesia. Nat Rev Neurosci 2008, 9:665-677.
9. Monville C, Torres EM, Pekarik V, Lane EL, Dunnett SB Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model. Brain Res Bull 2009, 78:248-253.
10. Nadjar A, Gerfen CR, Bezard E Priming for L-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?. Prog Neurobiol 2009, 87:1-9.
11. Calabresi P, Di Filippo M, Ghiglieri V, Picconi B Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 2008, 23(suppl 3):S570-S579.
12. Putterman DB, Munhall AC, Kozell LB, Belknap JK, Johnson SW Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2007, 323:277-284.
13. Cenci MA, Lundblad M Post-versus presynaptic plasticity in L-dopa-induced dyskinesia. J Neurochem 2006, 99:381-392.
14. Abercrombie ED, Bonatz AE, Zigmond MJ Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990, 525:36-44.
15. Wachtel SR, Abercrombie ED L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 1994, 63:108-117.
16. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989, 25:523-526.
17. Metman LV, Konitsiotis S, Chase TN Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord 2000, 15:3-8.
18. de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127:2747-2754.
19. Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA Role of striatal L-dopa in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 2006, 96:1718-1727.
20. Nutt JG, Chung KA, Holford NH Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology 2010, 74:1191-1197.
21. Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA L-dopa-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 2010, 112:1465-1476.
22. Buck K, Voehringer P, Ferger B Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats. Neuroscience 2010, 166:355-358.
23. Sossi V, Dinelle K, Topping GJ, et al. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J Neurochem 2009, 109:85-92.
24. Vinuela A, Hallett PJ, Reske-Nielsen C, et al. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain 2008, 131:3361-3379.
25. Lee J, Zhu WM, Stanic D, et al. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 2008, 131:1574-1587.
26. Calabresi P, Giacomini P, Centonze D, Bernardi G Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?. Ann Neurol 2000, 47(4 suppl 1):S60-S68.
27. Calabresi P, Picconi B, Tozzi A, Di Filippo M Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007, 30:211-219.
28. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-dopa-induced dyskinesia. Nat Neurosci 2003, 6:501-506.
29. Picconi B, Paille V, Ghiglieri V, et al. L-dopa dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 2008, 29:327-335.
30. Calabresi P, Mercuri NB, Di Filippo M Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. Brain 2009, 132:285-287.
31. Prescott IA, Dostrovsky JO, Moro E, Hodaie M, Lozano AM, Hutchison WD Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. Brain 2009, 132:309-318.
32. Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 2006, 129:1059-1069.
33. Konradi C, Westin JE, Carta M, et al. Transcriptome analysis in a rat model of L-dopa-induced dyskinesia. Neurobiol Dis 2004, 17:219-236.
34. Darmopil S, Martin AB, De Diego IR, Ares S, Moratalla R Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-dopa-induced dyskinesia and histone activation. Biol Psychiatry 2009, 66:603-613.
35. Aubert I, Guigoni C, Hakansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005, 57:17-26.
36. Berthet A, Porras G, Doudnikoff E, et al. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-dopa-induced dyskinesia. J Neurosci 2009, 29:4829-4835.
37. Lindgren HS, Ohlin KE, Cenci MA Differential involvement of D1 and D2 dopamine receptors in L-dopa-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology 2009, 34:2477-2488.
38. Berton O, Guigoni C, Li Q, et al. Striatal overexpression of DeltaJunD resets L-dopa-induced dyskinesia in a primate model of Parkinson disease. Biol Psychiatry 2009, 66:554-561.
39. Nicholas AP, Lubin FD, Hallett PJ, et al. Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem 2008, 106:486-494.
40. Santini E, Valjent E, Usiello A, et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-dopa-induced dyskinesia. J Neurosci 2007, 27:6995-7005.
41. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-dopa-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 2007, 62:800-810.
42. Lebel M, Chagniel L, Bureau G, Cyr M Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis 2010, 38:59-67.
43. Crittenden JR, Cantuti-Castelvetri I, Saka E, et al. Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy. Proc Natl Acad Sci USA 2009, 106:2892-2896.
44. Klann E Thwarting dyskinesia by targeting mTORC1. Sci Signal 2009, 2:pe42.
45. Santini E, Heiman M, Greengard P, Valjent E, Fisone G Inhibition of mTOR signaling in Parkinson's disease prevents L-dopa-induced dyskinesia. Sci Signal 2009, 2:ra36.
46. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000, 342:1484-1491.
47. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998, 55(suppl 1):23-30.
48. Kumar R, Riddle LR, Griffin SA, et al. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology 2009, 56:956-969.
49. Schmidt WJ, Lebsanft H, Heindl M, et al. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. J Neural Transm 2008, 115:1385-1392.
50. Stockwell KA, Scheller D, Rose S, et al. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp Neurol 2009, 219:533-542.
51. Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2008, 23:1922-1925.
52. Brodsky MA, Park BS, Nutt JG Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease. Arch Neurol 2010, 67:27-32.
53. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003, 9:762-767.
54. Gold SJ, Hoang CV, Potts BW, et al. RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci 2007, 27:14338-14348.
55. Morissette M, Samadi P, Hadj Tahar A, Belanger N, Di Paolo T. Striatal Akt/GSK3 signaling pathway in the development of L-dopa-induced dyskinesias in MPTP monkeys. Prog Neuropsychopharmacol Biol Psychiatry; 34: 446-54.
56. Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA Role of adenosine A2A receptors in parkinsonian motor impairment and L-dopa-induced motor complications. Prog Neurobiol 2007, 83:293-309.
57. Xiao D, Bastia E, Xu YH, et al. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci 2006, 26:13548-13555.
58. Hodgson RA, Bertorelli R, Varty GB, et al. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazol o[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther 2009, 330:294-303.
59. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008, 23:2177-2185.
60. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord 2010, 25:1437-1443.
61. Fiorentini C, Busi C, Spano P, Missale C Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease. Parkinsonism Relat Disord 2008, 14(suppl 2):S159-S164.
62. Gardoni F, Picconi B, Ghiglieri V, et al. A critical interaction between NR2B and MAGUK in L-dopa induced dyskinesia. J Neurosci 2006, 26:2914-2922.
63. Paquette MA, Anderson AM, Lewis JR, Meshul CK, Johnson SW, Paul Berger S MK-801 inhibits L-dopa-induced abnormal involuntary movements only at doses that worsen parkinsonism. Neuropharmacology 2010, 58:1002-1008.
64. Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 2010, 25:1357-1363.
65. Nutt JG, Gunzler SA, Kirchhoff T, et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism. Mov Disord 2008, 23:1860-1866.
66. Ouattara B, Belkhir S, Morissette M, et al. Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. J Mol Neurosci 2009, 38:128-142.
67. Conn PJ, Battaglia G, Marino MJ, Nicoletti F Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 2005, 6:787-798.
68. Samadi P, Gregoire L, Morissette M, et al. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-dopa-induced dyskinesias. Neuropharmacology 2008, 54:258-268.
69. Ouattara B, Gregoire L, Morissette M, et al. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 2009, published online Dec 24. 10.1016/j.neurobiolaging.2009.07.014.
70. Levandis G, Bazzini E, Armentero MT, Nappi G, Blandini F Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts L-dopa-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis 2008, 29:161-168.
71. Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA Antagonism of metabotropic glutamate receptor type 5 attenuates L-dopa-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 2007, 101:483-497.
72. Morin N, Gregoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 2010, 58:981-986.
73. Rylander D, Iderberg H, Li Q, et al. A mGluR5 antagonist under clinical development improves L-dopa-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 2010, 39:352-361.
74. Jimenez A, Bonastre M, Aguilar E, Marin C Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats. Psychopharmacology 2009, 206:233-242.
75. Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA Pharmacological modulation of glutamate transmission in a rat model of L-dopa-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 2009, 330:227-235.
76. Yamamoto N, Soghomonian JJ Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by L-dopa in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience 2009, 163:1171-1180.
77. Samadi P, Rajput A, Calon F, et al. Metabotropic glutamate receptor II in the brains of Parkinsonian patients. J Neuropathol Exp Neurol 2009, 68:374-382.
78. Eggert K, Squillacote D, Barone P, et al. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov Disord 2010, 25:896-905.
79. Fox SH, Chuang R, Brotchie JM Serotonin and Parkinson's disease: on movement, mood, and madness. Mov Disord 2009, 24:1255-1266.
80. Carta M, Carlsson T, Kirik D, Bjorklund A Dopamine released from 5-HT terminals is the cause of L-dopa-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
81. Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A Serotonin-dopamine interaction in the induction and maintenance of L-dopa-induced dyskinesias. Prog Brain Res 2008, 172:465-478.
82. Munoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-dopa-induced dyskinesia. Brain 2008, 131:3380-3394.
83. Munoz A, Carlsson T, Tronci E, Kirik D, Bjorklund A, Carta M Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol 2009, 219:298-307.
84. Gregoire L, Samadi P, Graham J, Bedard PJ, Bartoszyk GD, Di Paolo T Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-dopa in parkinsonian monkeys. Parkinsonism Relat Disord 2009, 15:445-452.
85. Marin C, Aguilar E, Rodriguez-Oroz MC, Bartoszyk GD, Obeso JA Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology 2009, 204:241-250.
86. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007, 22:179-186.
87. Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D Serotonin neuron transplants exacerbate L-dopa-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 2007, 27:8011-8022.
88. Carlsson T, Carta M, Munoz A, et al. Impact of grafted serotonin and dopamine neurons on development of L-dopa-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009, 132:319-335.
89. Di Filippo M, Picconi B, Tozzi A, Ghiglieri V, Rossi A, Calabresi P The endocannabinoid system in Parkinson's disease. Curr Pharm Des 2008, 14:2337-2347.
90. Gerdeman GL, Lovinger DM Emerging roles for endocannabinoids in long-term synaptic plasticity. Br J Pharmacol 2003, 140:781-789.
91. Morgese MG, Cassano T, Cuomo V, Giuffrida A Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp Neurol 2007, 208:110-119.
92. Morgese MG, Cassano T, Gaetani S, et al. Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochem Int 2009, 54:56-64.
93. Perez-Rial S, Garcia-Gutierrez MS, Molina JA, et al. Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. Neurobiol Aging 2009, published online May 4. 10.1016/j.neurobiolaging.2009.03.017.
94. Bordia T, Campos C, Huang L, Quik M Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-dopa)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2008, 327:239-247.
95. Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, Di Monte D Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 2007, 62:588-596.
96. Marti M, Trapella C, Morari M The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-dopa. J Neurochem 2008, 107:1683-1696.
97. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009, 66:563-570.
98. Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 2007, 22:1317-1319.
99. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007, 22:2409-2417.
100. Lane E, Dunnett S Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?. Psychopharmacology 2008, 199:303-312.
101. Monville C, Torres EM, Dunnett SB Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res Bull 2005, 68:16-23.
102. Lang AE, Obeso JA Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004, 3:309-316.
103. Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 2008, 23:700-707.
104. Benabid AL, Chabardes S, Mitrofanis J, Pollak P Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009, 8:67-81.